Vortioxetine for the treatment of major depressive disorder

References

• Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54(9):3206-21
   PubMed Web of Science ®Google Scholar
• Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113(1):134-53
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16(5):333-8
   PubMed Web of Science ®Google Scholar
• Greenshaw AJ. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol Sci 1993;14(7):265-70
   PubMed Web of Science ®Google Scholar
• Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharm 2010;24(4):455-69
   PubMed Web of Science ®Google Scholar
• Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009;205(1):119-28
   PubMed Web of Science ®Google Scholar
• Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol Psychiatry 2005;58(10):831-7
   PubMed Web of Science ®Google Scholar
• Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 2006;51(3):578-86
   PubMed Web of Science ®Google Scholar
• Harsing LG Jr, Prauda I, Barkoczy J, et al. A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. Neurochem Res 2004;29(8):1487-97
   PubMed Web of Science ®Google Scholar
• Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 2013;105:41-50
   PubMed Web of Science ®Google Scholar
• Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol 2004;15(8):523-34
   PubMed Web of Science ®Google Scholar
• Chenu F, David DJ, Leroux-Nicollet I, et al. Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatry Neurosci 2008;33(6):541-50
   PubMed Web of Science ®Google Scholar
• O’Neill MF, Conway MW. Role of 5-HT(1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 2001;24(4):391-8
   PubMed Web of Science ®Google Scholar
• de Groote L, Klompmakers AA, Olivier B, Westenberg HG. Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade. Psychopharmacology (Berl) 2003;167(2):153-8
   PubMed Web of Science ®Google Scholar
• Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340(3):666-75
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters – a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2013;23(2):133-45
   PubMed Web of Science ®Google Scholar
• Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010;65(1):7-19
   PubMed Web of Science ®Google Scholar
• Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15(7):220-6
   PubMed Web of Science ®Google Scholar
• Betry C, Pehrson AL, Etievant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol 2013;16(5):1115-27
   PubMed Web of Science ®Google Scholar
• Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science 2012;338(6103):72-5
   PubMed Web of Science ®Google Scholar
• Mendez-David I, Hen R, Gardier AM, David DJ. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr 2013;71(3):143-9
   PubMedGoogle Scholar
• Guilloux JP, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013;73:147-59
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19(2):121-33
   PubMed Web of Science ®Google Scholar
• Anisman H, Hayley S, Kelly O, et al. Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: mouse strain-dependent outcomes. Behav Neurosci 2001;115(2):443-54
   PubMed Web of Science ®Google Scholar
• Kim S, Lee S, Ryu S, et al. Comparative analysis of the anxiety-related behaviors in four inbred mice. Behav Processes 2002;60(2):181-90
   PubMed Web of Science ®Google Scholar
• Neumann ID, Wegener G, Homberg JR, et al. Animal models of depression and anxiety: what do they tell us about human condition? Prog Neuropsychopharmacol Biol Psychiatry 2011;35(6):1357-75
   PubMed Web of Science ®Google Scholar
• Overstreet DH, Wegener G. The flinders sensitive line rat model of depression – 25 years and still producing. Pharmacol Rev 2013;65(1):143-55
   PubMed Web of Science ®Google Scholar
• Li Y, Raaby KF, Sanchez C, Gulinello M. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res 2013;256:520-8
   PubMed Web of Science ®Google Scholar
• Jensen JB, du Jardin KG, Song D, et al. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol 2014;24(1):148-59
   PubMed Web of Science ®Google Scholar
• du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014;24(1):160-71
   PubMed Web of Science ®Google Scholar
• Wallace A, Pehrson AL, Sanchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;1-12
   PubMed Web of Science ®Google Scholar
• Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. The multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine - a quantitative electroencephalographic study in the rat. Br J Pharmacol 2014; In press
   PubMed Web of Science ®Google Scholar
• Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52(2):90-110
   PubMed Web of Science ®Google Scholar
• Venzala E, Garcia-Garcia AL, Elizalde N, et al. Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors. Psychopharmacology (Berl) 2012;224(2):313-25
   PubMed Web of Science ®Google Scholar
• David DJ, Samuels BA, Rainer Q, et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009;62(4):479-93
   PubMed Web of Science ®Google Scholar
• Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32(2):86-102
   PubMed Web of Science ®Google Scholar
• Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study. Am J Psychiatry 2004;161(5):826-35
   PubMed Web of Science ®Google Scholar
• Areberg J, Luntang-Jensen M, Sogaard B, Nilausen DO. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 2012;110(4):401-4
   PubMed Web of Science ®Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int Clin Psychopharmacol 2012;15(5):589-600
   Google Scholar
• Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22(7):482-91
   PubMed Web of Science ®Google Scholar
• Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73(7):953-9
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27(4):215-23
   PubMed Web of Science ®Google Scholar
• Chen G, Lee R, Hojer AM, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013;33(10):727-36
   PubMed Web of Science ®Google Scholar
• Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014; In press
   PubMed Web of Science ®Google Scholar
• Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012;40(7):1357-65
   PubMed Web of Science ®Google Scholar
• Wang Y, Wojtkowski T, Devoti A, et al. Effect of Lu AA21004 on the pharmacokinetics and pharmacodynamics of ethinyl estradiol (30 lg) and levonorgestrel (150 lg) in healthy adult women. J Clin Pharmacol 2009;49:1114
   Web of Science ®Google Scholar
• Wang Y, Zhang W, Agyeman A, et al. Lack of effect of multiple doses of Lu AA21004 on the pharmacodynamics and pharmacokinetics of aspirin. J Clin Pharmacol 2010;50:1082
   Web of Science ®Google Scholar
• Efficacy and safety study of vortioxetine (Lu AA21004) for treatment of major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01255787
   Google Scholar
• Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72(4):464-72
   PubMed Web of Science ®Google Scholar
• Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol 2012;22(12):847-57
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26(11):1408-16
   PubMed Web of Science ®Google Scholar
• Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int Clin Psychopharmacol 2013;16(2):313-21
   Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29(3):217-26
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: www.ClinicalTrials.gov database
   Google Scholar
• Safety and efficacy study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01179516
   Google Scholar
• Efficacy and safety study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01163266
   Google Scholar
• Safety and efficacy of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01153009
   Google Scholar
• Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29(3):138-49
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int Clin Psychopharmacol 2014;1-11
   PubMedGoogle Scholar
• Marazziti D, Consoli G, Picchetti M, et al. Cognitive impairment in major depression. Eur J Pharmacol 2010;626(1):83-6
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord 2014;152-154:19-27
   PubMed Web of Science ®Google Scholar
• Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol 2013;27(7):575-83
   PubMed Web of Science ®Google Scholar
• Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013;93(6):493-501
   PubMed Web of Science ®Google Scholar
• Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002;63(5):396-402
   PubMed Web of Science ®Google Scholar
• Gallassi R, Di Sarro R, Morreale A, Amore M. Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord 2006;91(2-3):243-50
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Caftori R, Avital A, Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res Bull 2002;58(4):345-50
   PubMed Web of Science ®Google Scholar
• Richardson JS, Keegan DL, Bowen RC, et al. Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. Int Clin Psychopharmacol 1994;9(1):35-40
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, et al. Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: results of a randomized, double blind, active referenced, placebo-controlled trial. Presented at the 29th World Congress of the International College of Neuropsychopharmacology; Vaccouver, Canada; 2014; Poster LP-02
   Google Scholar
• Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29(1):36-44
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28(10):1717-24
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol 2014;29(1):64-72
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Serenko M, Palo W, et al. The safety and tolerability of vortioxetine (LuAA21004) in the treatment of adults with major depressive disorder (MDD): pooled analysis. Int J Psychiatry 2013;17:16-17
   Google Scholar
• Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29(2):157-64
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableswarkar AR, Chen Y, et al. A head to head, randomized, comparison study of vortioxetine vs. escitalopram in patients well treated for MDD and experiencing treatment-emergent sexual dysfunction. Presented at the Annual Meeting Of The American Society of Clinical Psychopharmacology; 16 – 19 June 2014; Hollywood, FL, USA; Poster 41
   Google Scholar
• Luca A, Luca M, Calandra C. Sleep disorders and depression: brief review of the literature, case report, and nonpharmacologic interventions for depression. Clin Interv Aging 2013;8:1033-9
   PubMed Web of Science ®Google Scholar
• Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20(8):533-59
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableswarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adult with major depressive disorder. Presented at the American Psychiatric Association 166th Annual Meeting; 18 – 22 May 2013; San Francisco, CA, USA Poster NR9-06
   Google Scholar
• Mahableshwarkar AR, Chen MY, Trivedi MH. A duloxetine-referenced, fixed-dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patients. Presented at the American Psychiatric Association 166th Annual Meeting; 18 – 22 May 2013; San Francisco, CA, USA; Poster NR9-01
   Google Scholar
• Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68(1):60-82
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical America I. BRINTELLIX (vortioxetine) tablets, for oral use. Prescribing information. Revised September 2013 Available from: http://general.takedapharm.com/content/file/pi.pdf?applicationcode=396066C6-E50F-4113-ABAD-54FE9525BF7E&filetypecode=BRINTELLIXPI 2013
   Google Scholar
• Fu J, Chen Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis. Psychopharmacology (Berl) 2014. In press
   Web of Science ®Google Scholar